The fetal zone is a unique adrenal cortical compartment that exists only during fetal life in humans and higher primates and produces large amounts of the adrenal androgen dehydroepiandrosterone sulfate (DHEA-S). Growth of the fetal zone is primarily regulated by ACTH, the actions of which are mediated in part by locally produced autocrine/paracrine growth factors. We previously demonstrated that one of these growth factors, insulin-like growth factor II (IGF-II), is mitogenic for cultured fetal zone cells and is produced in high abundance by these cells in response to ACTH. In the present study, we determined whether IGF-II also modulates the differentiated function of fetal zone cells. We examined the effects of recombinant human IGF-II and the closely related peptide, IGF-I, on 1) basal and agoniststimulated [ACTH-(1-24), forskolin, or 8-bromo-cAMP] cortisol and DHEA-S production, 2) basal and ACTH-stimulated steady state abundance of messenger ribonucleic acids (mRNAs) encoding the steroidogenic enzymes cytochrome P450 side-chain cleavage (P450scc) and cytochrome P450 17␣-hydroxylase/17,20-lyase (P450c17), and 3) basal and ACTH-stimulated steady state abundance of mRNA encoding the ACTH receptor. Basal cortisol (23.93 Ϯ 1.20 pmol/10 5 cells⅐24 h) and DHEA-S (548.87 Ϯ 43.17 pmol/10 5 cells⅐24 h) productions were significantly (P Ͻ 0.05) increased by IGF-I (2.3-and 1.8-fold, respectively) and IGF-II (2.8-and 1.8-fold, respectively). As expected, ACTH, forskolin, and cAMP markedly increased the production of cortisol by 26-, 10-, and 13-fold, respectively, and that of DHEA-S by 5.4-, 4.6-, and 5.5-fold, respectively, compared with basal levels. IGF-II (100 ng/mL) significantly (P Ͻ 0.001) increased ACTH-, forskolin-, and cAMP-stimulated production of cortisol by 2.4-, 4.3-, and 3.2-fold, respectively, and that of DHEA-S by 1.4, 1.6-, and 1.4-fold, respectively. IGF-I (100 ng/mL) had similar effects as IGF-II and significantly (P Ͻ 0.001) increased ACTH-, forskolin-, and cAMP-stimulated production of cortisol by 2.8-, 3.9-, and 3.1-fold, respectively, and that of DHEA-S by 1.3-, 1.6-, and 1.4-fold, respectively. The similar potencies of IGF-I and IGF-II suggest that the actions of these factors were mediated via a common receptor, most likely the type I IGF receptor. The effects of IGF-II on ACTH-stimulated steroid production were dose-dependent (EC 50 , 0.5-1.0 nmol/L), and IGF-II markedly increased the steroidogenic responsiveness of fetal zone cells to ACTH. With respect to cortisol production, IGF-II shifted the ACTH dose-response curve to the left by 1 log 10 order of magnitude. IGF-II also increased ACTH-stimulated abundance of mRNA encoding P450scc (1.9-fold) and P450c17 (2.2-fold). Basal expression of P450scc was not affected by IGF-II. In contrast, basal expression of P450c17 was increased 2.2-fold by IGF-II and IGF-I in a dose-responsive fashion. Neither IGF-I nor IGF-II affected basal or ACTH-stimulated abundance of mRNA encoding the ACTH receptor, suggesting that the increase in ACTH responsiveness was not mediated by an increase in ACTH-binding capacity. Taken together, these data indicate that activation of the type I IGF receptor increases ACTH responsiveness in fetal zone cells by modulating ACTH signal transduction at some point distal to ACTH receptor activation. These data also indicate that locally produced IGF-II modulates fetal adrenal cortical cell function by increasing responsiveness to ACTH and possibly (based on its direct stimulation of P450c17 expression) augmenting the potential for adrenal androgen synthesis. Thus, activation of the type I IGF receptor on adrenal cortical cells may play a pivotal role in adrenal androgen production, both physiologically in utero and at adrenarche, and in pathophysiological conditions of hyperandrogenemia, such as the polycystic ovary syndrome.
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The growth and function of the fetal zone and the specific ontogenetic differentiation of the transitional and definitive zones, are primarily regulated by ACTH secreted by the fetal pituitary gland (5) (6) (7) (8) . We have examined the mechanism by which ACTH regulates fetal zone growth and hypothesized that, as it is not a mitogen per se, its growth stimulatory effects are mediated by locally produced growth factors which then act in an autocrine/paracrine mode (9, 10) . In support of this concept, we have found that some growth factors that are mitogenic for fetal zone cells also are expressed by fetal zone cells in response to ACTH (10, 13) .
Of the growth factors examined, insulin-like growth factor II (IGF-II) is particularly interesting as 1) it is highly expressed by the human fetal adrenals (11-13); 2) its expression by human fetal adrenal cortical cells is positively regulated by ACTH (13-15); 3) it is mitogenic for fetal zone cells and acts cooperatively with other fetal zone mitogens, such as basic fibroblast growth factor and epidermal growth factor (13); 4) it is an exclusive fetal adrenal cortical growth factor, i.e., soon after birth its expression by adrenal cortical cells decreases to undetectable levels and becomes refractory to ACTH stimulation (16); 5) the closely related peptide, IGF-I, modulates the growth and function of cultured human adult adrenal cortical cells (17, 18) ; and 6) the actions of IGF-I and IGF-II on fetal adrenal cortical cells appear to be mediated via a common receptor, the type I IGF receptor, which has been localized in the human fetal adrenal cortex (19) . Thus, IGF-II is likely to play a major role in the regulation of fetal zone development. The present studies were undertaken to further characterize the effects of IGF-II on the differentiated function of fetal zone cells. We hypothesized that in the developing human fetal adrenal cortex, IGF-II, acting via the type I IGF receptor, not only affects the proliferation of fetal zone cells, but also modulates their differentiated function and may influence adrenal androgen synthesis. In the present study, we tested this hypothesis using primary cultures of fetal zone cells derived from midgestation human fetal adrenals. We examined the effects of IGF-II on basal and stimulated steroidogenic activities and the expression of key steroid-metabolizing enzymes. For comparison, we also examined the effect of IGF-I on the same parameters.
Materials and Methods Materials
Human fetal adrenal glands were obtained from second trimester fetuses (16 -22 weeks; gestation estimated by foot length; n ϭ 20) after elective termination of pregnancy by dilatation and evacuation. Glands were collected immediately after pregnancy termination and placed in ice-cold tissue culture medium (see below). Pairs of adrenals from individual fetuses were pooled and treated separately from adrenals derived from other fetuses. The study protocol was approved by the Committee on Human Research of the University of California-San Francisco (UCSF).
Human recombinant IGF-II was obtained from Upstate Biotechnology (Lake Placid, NY). Human recombinant IGF-I was a generous gift from Chiron Corp. (Emeryville, CA). Human ACTH-(1-24) (Cortrosyn) was obtained from Organon (West Orange, NJ). Forskolin and 8-bromocAMP were obtained from Sigma Chemical Co. (St. Louis, MO). The full-length complementary DNAs (cDNAs) encoding human cytochrome P450 side-chain cleavage (P450scc) and cytochrome P45017␣ hydroxylase/17,20 lyase (P450c17) were provided by Dr. W. L. Miller, UCSF (20, 21) . The full-length cDNA encoding the human ACTH receptor was provided by Dr. R. Cone, Vollum Institute, Oregon Health Sciences University (Portland, OR) (22) . The full-length cDNA encoding human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was obtained from American Type Culture Collection (Rockville, MD).
Preparation of fetal adrenal cortical cultures
Primary cultures of midgestation human fetal adrenal cortical cells were prepared as previously described (23) . Briefly, the adrenal capsule with adherent definitive/transitional zones was carefully dissected away from the underlying cortical tissue, and the remaining fetal zone was dispersed by enzymatic digestion with collagenase. Cells were plated onto 6-cm diameter plastic culture dishes (Falcon Plastics, Los Angeles, CA) at a density of 5 ϫ 10 5 cells/dish or onto 48-well culture dishes (Nunc, Naperville, IL) at a density of 1 ϫ 10 5 cells/well. In each case, the culture medium was DMEM H-16-Ham's F-12 (1:1) medium containing nonessential amino acids and supplemented with 10% fetal calf serum (FCS), 2 mmol/L glutamine, and 50 g/mL gentamicin (Cell Culture Facility, UCSF). All plates were incubated in a humidified environment at 37 C in 95% air-5% CO 2 . After 48 h, media were changed to a medium containing 2% FCS, and test substances were added for various times. Media were then collected and stored at Ϫ20 C for subsequent assay of cortisol and DHEA-S. The remaining cells were either collected after trypsinization and counted in a particle counter or processed for total ribonucleic acid (RNA) isolation.
RNA analysis
Northern blot, slot blot, and ribonuclease protection analyses were used to assay the abundance of specific messenger RNA (mRNA) transcripts. Total RNA was extracted and purified from cultured cells using the method of Chomczynski and Sacchi (24) . For Northern blotting, total RNA was denatured in formaldehyde, subjected to electrophoresis through a 1.2% agarose gel, and transferred to nitrocellulose membranes (Nytran, Schleicher and Schuell, Keene, NH). For slot blots, total RNA was denatured in formaldehyde and applied to a nitrocellulose membrane using a slot blot manifold (Schleicher and Schuell). In both cases, the RNA was cross-linked to the membranes by exposure to UV radiation (Stratalinker, Stratagene, La Jolla, CA), then hybridized with [ 32 P]deoxy-CTP-labeled cDNA probes (1-2 ϫ 10 9 dpm/g) synthesized by random primer extension of denatured full-length cDNAs. Prehybridization was performed in hybridization buffer (Quickhyb buffer, Stratagene, La Jolla, CA) at 68 C for 15 min. Denatured radiolabeled probe was then added to the membranes and incubated at 68 C for 90 min. To remove nonspecifically bound probe, membranes were washed in 2 ϫ SSC (1 ϫ SSC is 0.15 mol/L NaCl and 0.015 mol/L sodium citrate)-0.1% SDS at room temperature for 15 min and then in 0.1 ϫ SSC-0.1% SDS at 60 C for 30 min. Membranes were subjected to autoradiography at Ϫ70 C. The relative abundance of mRNA transcripts was estimated by computer-assisted densitometry. All data were normalized to the abundance of transcripts encoding GAPDH that was constitutively expressed. Probes were removed by washing the membranes in distilled water at 100 C. Complete removal of probe was confirmed by autoradiography before reprobing.
Ribonuclease protection analyses were performed using a kit obtained from Ambion (HybSpeed RPA, Ambion, Austin, TX). Antisense 32 P-labeled complementary RNA probes for P450scc (192 bases) and P450c17 (313 bases) were synthesized using cDNA templates subcloned into pBluescript SK (Stratagene, La Jolla, CA). The complementary RNA probes were gel-purified by electrophoresis and hybridized with 5 g total RNA extracted from cultured fetal zone cells. Samples were then digested with ribonuclease A/T1, and the protected fragments were precipitated, resuspended, and subjected to electrophoresis under denaturing conditions (6 mol/L urea) in 6% polyacrylamide. The gel then was dried and subjected to autoradiography. The amount of radioactivity in the protected bands, which directly reflects the amount of target mRNA, was measured by scintillation counting of the excised bands.
RIAs
Cortisol and DHEA-S were measured in conditioned medium using specific RIAs, which we have described previously (23) . Unconjugated cortisol was assayed using a kit purchased from Diagnostic Products Corp. (Los Angeles, CA). DHEA-S was assayed using a kit purchased from ICN Biomedicals (Costa Mesa, CA). All assays were validated for use in conditioned media from fetal adrenal cortical cell cultures, and each had inter-and intraassay coefficients of variation less than 10%.
Statistical analyses
All hormone data were normalized relative to cell number and expressed as picomoles per 10 5 cells/24 h and are presented as the mean Ϯ se. Data derived from Northern blot analyses were normalized relative to GAPDH and expressed in arbitrary units. All experiments were performed in triplicate wells and repeated at least three times. Statistical analyses were conducted by ANOVA followed by Newman-Keuls posthoc test for significance between groups. Differences were considered statistically significant when P Ͻ 0.05.
Results
Recombinant human IGF-I and IGF-II (each 100 ng/mL; ϳ13 nmol/L) significantly increased basal and agonist-stimulated [ACTH (1 nmol/L), forskolin (1 mol/L), or cAMP (0.1 mmol/L)] cortisol and DHEA-S production by fetal zone cells (Fig. 1) . The effects of IGF-II on ACTH-stimulated steroid production were dose dependent, with an EC 50 of 1.0 -10 ng/mL (Fig. 2) . In the experiment shown in Fig. 2 , the concentration of ACTH used (0.1 nmol/L) was not sufficient to increase cortisol in the absence of IGF-II. In the presence of increasing concentrations of IGF-II, cortisol increased markedly in response to 0.1 nmol/L ACTH. IGF-II also increased DHEA-S production in response to 0.1 nmol/L ACTH in a dose-responsive fashion. Thus, with respect to cortisol and DHEA-S production, IGF-II augmented the responsiveness of the fetal zone cells to ACTH.
To further examine the effect of IGF-II on ACTH responsiveness, we assessed the effect of IGF-II (100 ng/mL) on the response of fetal zone cells to various concentrations of ACTH (Fig. 3) . With respect to cortisol production, IGF-II shifted the ACTH dose-response curve to the left by approximately 1 log 10 order of magnitude. The production of DHEA-S was more sensitive to ACTH stimulation than was that of cortisol and was elicited with ACTH concentrations as low as 0.1 pmol/L. In control cultures (no IGF-II), DHEA-S production exhibited an apparent biphasic response to increasing ACTH concentrations. Interestingly, the decrease in DHEA-S production coincided with the increase in cortisol production. IGF-II eliminated the biphasic pattern of DHEA-S production in response to increasing concentrations Cells were exposed to IGF-I or IGF-II for 24 h, media were changed, the IGFs were replenished, and some wells were exposed to agonist for a further 24 h. Data are the mean Ϯ SE of triplicate samples and are representative of three separate experiments. *, P Ͻ 0.05.
FIG. 2. Effects of various concentrations of IGF-II on ACTH-stimu-
lated cortisol and DHEA-S production by primary cultures of fetal zone cells. Cells were exposed to various concentrations of IGF-II for 24 h, media were changed, IGF-II was replenished, and some wells were exposed to ACTH (0.1 nmol/L) for an additional 24 h. Data are the mean Ϯ SE of triplicate samples and are representative of three separate experiments.
of ACTH. In cells exposed to IGF-II, DHEA-S production continued to increase with increasing concentrations of ACTH and reached a plateau at 0.1 nmol/L. Thus, the net effect of IGF-II was to augment DHEA-S synthesis.
To investigate the mechanism for the stimulatory effect of IGF-II on ACTH responsiveness, we examined its effects on basal and ACTH-stimulated expression of the steroidogenic enzymes P450scc and P450c17. Using ribonuclease protection analysis, we found that IGF-II increased ACTH-stimulated abundance of mRNA encoding P450scc 1.9-fold and that of mRNA encoding P450c17 2.2-fold (Fig. 4) . IGF-II had no effect on basal expression of P450scc. However, basal expression of P450c17 was increased by IGF-II 2.2-fold. We also examined the effects of IGF-I and -II on P450c17 expression by Northern and slot blot analysis and found that IGF-I increased basal and ACTH-stimulated expression of P450c17 in a dose-responsive fashion (Fig. 5) . Consistent with its augmentation of ACTH responsiveness, IGF-II also increased responsiveness to ACTH with respect to P450c17 expression and shifted the ACTH dose-response curve to the left (Fig. 6) .
To further explore the mechanism by which the IGFs augment ACTH responsiveness, we determined whether IGF-I and -II modulate expression of the ACTH receptor. As we previously reported (25) , abundance of mRNA encoding the ACTH receptor was increased by ACTH and was associated with multiple transcripts. Preexposure of fetal zone cells to IGF-I or IGF-II increased ACTH-stimulated ACTH receptor expression, but had no effect on basal ACTH receptor expression (data not shown).
Discussion
The IGFs (particularly IGF-I) have been shown to influence the differentiated function of several human steroidogenic cell types, including adrenal cortical cells. In adult human adrenal cortical cells, IGF-I enhances the responsiveness to ACTH and the expression and activity of cytochrome P450c17 (17, 18) . The increased P450c17 activity suggests that IGF-I may influence adrenal androgen production, as this enzyme is essential for the synthesis of ⌬ 5 C 19 steroids. In adult bovine (26) and fetal ovine (27) adrenal cortical cells, IGF-I also has been shown to enhance steroidogenic responsiveness to ACTH and proliferation of adrenal cortical cells. Although we have shown that IGF-I is not expressed in the human fetal adrenal cortex (13), IGF-II appears to exert its actions by interacting with the IGF-I receptor (type I IGF receptor). Thus, the actions of IGF-II in the human fetal adrenal may be analogous to those of IGF-I in the postnatal adrenal.
IGF-II markedly increased the responsiveness of fetal zone cells to agonist (ACTH, forskolin, and cAMP) stimulation. These effects were closely mimicked by IGF-I, and based on their relative potencies, this suggests that the actions of these growth factors were mediated via the type I IGF receptor. This is consistent with previous studies in which we showed that the mitogenic actions of IGF-II on fetal zone cells were probably mediated via the type I IGF receptor (13) . This receptor shares structural and functional homology with the insulin receptor, binds both IGF-I and IGF-II with similarly high affinities and insulin with low affinity, and is thought to mediate most of the biological actions of IGF-II (28) . Ligand binding autoradiographic studies have shown that fetal zone cells express the type I IGF receptor (19) . Although a specific high affinity IGF-II receptor has been identified (i.e. the type II IGF/mannose-6-phosphate receptor), the biological actions that it mediates are unknown, and its expression by fetal zone cells has not been determined.
IGF-II increased ACTH-stimulated production of cortisol and DHEA-S by primary cultures of fetal zone cells in a dose-responsive fashion. With respect to cortisol production, IGF-II shifted the ACTH dose-response curve to the left by 1 log 10 order of magnitude, reflecting its augmentation of ACTH responsiveness. In contrast, IGF-II did not shift the ACTH dose-response curve with respect to DHEA-S production. Instead, IGF-II eliminated the decrease in DHEA-S production that occurred at higher ACTH concentrations. The decrease in DHEA-S production in control cultures coincided with the increase in cortisol production, and, therefore, was probably due to the diversion of substrate away Fetal zone cells were exposed to IGF-II for 24 h, media were changed, IGF-II was replenished, and some plates were exposed to various concentrations of ACTH (0 -10 nmol/L) for an additional 24 h. A, Slot blot analysis of abundance of P450c17 and GAPDH mRNA transcripts in 5 g total RNA (P450c17, 16-h exposure; GAPDH, 48-h exposure). B, Densitometric quantitation of P450c17 band intensity normalized to that for GAPDH.
from the ⌬ 5 pathway to the ⌬ 4 -3 ketosteroid pathway involved in cortisol synthesis. In the presence of IGF-II, DHEA-S production continued to rise in response to increasing concentrations of ACTH, despite the initiation of cortisol synthesis, and reached a plateau at 0.01-0.1 nmol/L ACTH. This continued increase in DHEA-S production may have been due to increased 17-hydroxylase activity induced by IGF-II (see below). It should be noted that the fetal zone does not express 3␤-hydroxysteroid dehydrogenase in vivo and, therefore, cannot synthesize cortisol de novo (4) . Thus, in vivo this effect of IGF-II on augmenting DHEA-S production by fetal zone cells may be more pronounced as steroidogenesis would be committed to the ⌬ 5 pathway. To examine the mechanism by which IGF-II augmented fetal zone cell steroidogenesis, we assessed its effects on basal and ACTH-stimulated expression of the key steroidogenic enzymes P450scc and P450c17. We found that IGF-II (and IGF-I) markedly increased ACTH-stimulated expression of P450scc and P450c17. This suggests that IGF-II increases ACTH-stimulated steroid production by increasing the expression, and therefore activity, of these steroidogenic enzymes. These data are consistent with our previous findings (23) , and in terms of steroidogenic enzyme expression, further demonstrate IGF-induced increased responsiveness to ACTH. Interestingly, we found that IGF-II also increased basal P450c17 expression, but did not affect basal expression of P450scc. These effects also were mimicked by IGF-I and are consistent with previous studies in which IGF-I was shown to increase P450c17 activity (17) and expression (18) in human adult adrenal cortical cells. In some experiments, we found that the magnitude by which the IGFs (both 13 nmol/L) increased basal P450c17 expression in fetal zone cells was comparable to that caused by 1 nmol/L ACTH. Thus, either IGF-I or IGF-II activation of the type I IGF receptor in fetal zone cells not only increases ACTH-stimulated expression of P450scc and P450c17, but also augments basal P450c17 expression. The increased basal P450c17 expression may account for the increase in basal cortisol and DHEA-S production induced by IGF-I and IGF-II. The consequence of such an increase in basal P450c17 expression may be to enhance the capacity of fetal zone cells for androgen production upon ACTH stimulation. In vivo, P450c17 is highly expressed by fetal zone cells. Our data suggest that IGF-II plays a role in maintaining this elevated level of P450c17 expression and, therefore, can serve as a pivotal factor in the regulation of fetal zone androgen production.
It is possible that our data reflect a general effect of type I IGF receptor activation on human adrenal cortical cell function. These findings have important implications regarding the role of the IGFs in the regulation of adrenal androgen production and suggest that activation of the type I IGF receptor by IGF-I, IGF-II, and/or insulin may increase ACTH responsiveness and P450c17 activity and, therefore, the capacity for adrenal androgen synthesis. A role for the IGFs and activation of the type I IGF receptor also has been suggested in pathological conditions of androgen excess, particularly hyperandrogenic amenorrhea (polycystic ovary syndrome) (29, 30) . This syndrome is associated with insulin resistance and hyperinsulinemia. It has been hypothesized that the increased insulin concentrations may be sufficient to activate the type I IGF receptor, leading to increased adrenal androgen production (29) . Our present data support this idea and indicate that activation of the type I IGF receptor on human adrenal cortical cells may have profound effects not only on fetal adrenal development and function, but also on adrenal cortical function postnatally.
The mechanism by which the IGFs increase ACTH responsiveness is not known. Previous studies have suggested that the IGFs augment the responsiveness of adrenal cortical cells to ACTH by increasing ACTH receptor expression and ACTH-binding capacity (18, 31) . We addressed this issue in fetal zone cells by determining whether the IGFs modulate ACTH receptor expression. Neither IGF-I nor IGF-II altered ACTH receptor expression by fetal zone cells. Although ACTH binding was not assessed, these findings indicate that the IGFs do not increase ACTH responsiveness in human fetal zone cells by increasing the number of ACTH-binding sites. Instead, our data indicate that the IGFs modulate the ACTH signal transduction pathway at some point distal to ACTH receptor binding, as IGF-I and -II increased responsiveness not only to ACTH, but also to forskolin and cAMP. The nature of this mechanism is unknown, and studies are underway to explore further the interaction between the growth factor/IGF and ACTH signal transduction pathways that may lead to increased tropic hormone responsiveness.
In summary, we have shown that IGF-II is a major modulator of fetal zone function and responsiveness to ACTH. Our present data indicate that IGF-II, via activation of the type I IGF receptor, may contribute to the increased responsiveness of the fetal zone during late gestation. In addition, our data suggest that IGF-II also increases the capacity of fetal zone cells for androgen synthesis by directly augmenting the expression of P450c17. Thus, IGF-II may play a pivotal role in establishing and maintaining the differentiated function of the fetal zone. This effect of IGF-II may reflect a general action of the IGFs on adrenal cortical responsiveness to ACTH and androgen production throughout life.
